Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

Executive Summary

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.

Advertisement

Related Content

Neuroscience Reaches A New Inflection Point, Big Biotechs Say
GeNeuro’s Causal Approach To MS Treatment Gathers Momentum
Biogen Anti-LINGO MS Study Failure Removes Upside

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel